Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay.

Autor: Sealover NE; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA., Hughes JM; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA., Theard PL; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA., Chatterjee D; Eppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA., Linke AJ; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA., Finniff BA; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA., Daley BR; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA., Lewis RE; Eppley Institute, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA., Kortum RL; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA. Electronic address: robert.kortum@usuhs.edu.

Publikováno v: STAR protocols [STAR Protoc] 2024 Oct 05; Vol. 5 (4), pp. 103361. Date of Electronic Publication: 2024 Oct 05.

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma.

Autor: Daley BR; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Sealover NE; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Sheffels E; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Hughes JM; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Gerlach D; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Hofmann MH; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Kostyrko K; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Mair B; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Linke A; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Beckley Z; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Frank A; Henry M. Jackson Foundation for the Advancement of Military Medicine; Bethesda, MD, USA.; Student Bioinformatics Initiative, Center for Military Precision Health, Uniformed Services University of the Health Sciences; Bethesda, MD, USA., Dalgard C; The American Genome Center, Department of Anatomy, Cell Biology, and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Kortum RL; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Dec 15. Date of Electronic Publication: 2023 Dec 15.

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.

Autor: Daley BR; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Vieira HM; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198., Rao C; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198., Hughes JM; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Beckley ZM; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Huisman DH; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198., Chatterjee D; Department of Integrative Physiology and Molecular Medicine, University of Nebraska Medical Center, Omaha, NE 68198., Sealover NE; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Cox K; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814., Askew JW; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198., Svoboda RA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198., Fisher KW; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198., Lewis RE; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198., Kortum RL; Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2023 Nov 21; Vol. 120 (47), pp. e2313137120. Date of Electronic Publication: 2023 Nov 16.

In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies.

Autor: Sealover NE, Theard PL, Hughes JM, Linke AJ, Daley BR, Kortum RL

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Jun 28. Date of Electronic Publication: 2023 Jun 28.